The Association of Clinical Research Organizations (ACRO), which represents clinical outsourcing companies, reported late last fall that its members have expanded their payroll by 122% in the past 10 years and now account for over 72,000 jobs both in the United States and abroad. ACRO attributes this job growth to the 156% increase in revenues since 2001, or a compound annualized rate of 11%.
“The capability of ACRO members to provide the full spectrum of drug development services required to bring new medicines to market has led to tremendous growth in the industry over the past 10 years,” said Joe Herring, ACRO Immediate Past Chair, and Chairman and CEO of Covance. “The biopharmaceutical industry has recognized our efficiency, quality and commitment to research ethics, and ACRO members now constitute a large—and growing— share of the global drug development infrastructure.”
Among other survey findings, ACRO members:
According to ACRO’s Executive Director, Doug Peddicord, PhD, the jobs that CROs have created over the past 10 years is due to their tremendous growth. “Our members continue to expand the range and scope of their services, from drug discovery through post-approval studies, developing deep expertise in complex areas like vaccines, biosimilars, comparative effectiveness research, and regenerative medicine.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.